Meeting
2013 ASCO Annual Meeting
Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis.
Authors
Stefan Michiels
Department of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, France
Stefan Michiels , Lina Pugliano , Delphine Grun , Jana Barinoff , David A. Cameron , Melody A. Cobleigh , Angelo Di Leo , Stephen R. D. Johnston , Giampietro Gasparini , Bella Kaufman , Michel E. Marty , Valentina Nekljudova , Shani Paluch-Shimon , Frederique Penault-Llorca , Dennis J. Slamon , Charles L. Vogel , Gunter Von Minckwitz , Marc E. Buyse , Martine J. Piccart-Gebhart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 31, 2013 (suppl; abstr 610)
DOI
10.1200/jco.2013.31.15_suppl.610
Abstract #
610
Poster Bd #
10A
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).
First Author: Ahmad Awada
Poster
2013 ASCO Annual Meeting
Estimated life years saved with trastuzumab in first-line HER2+ metastatic breast cancer from 1999 to 2013.
First Author: Mark Danese
Poster
2013 ASCO Annual Meeting
Second-line treatment of HER2+ metastatic breast cancer (MBC): Trastuzumab (T) beyond progression or lapatinib (L)? A retrospective database study.
First Author: Rinat Yerushalmi
Poster
2011 ASCO Annual Meeting
Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC).
First Author: R. Bartsch